Observational studyClinical rheumatology2016

Predictive factors for achieving low disease activity at 52 weeks after switching from tumor necrosis factor inhibitors to abatacept: results from a multicenter observational cohort study of Japanese patients.

Toshihisa Kojima et al.PubMed ↗Publisher ↗

No numbers read from the abstract.